|Bid||6.55 x 100|
|Ask||7.77 x 1500|
|Day's Range||7.06 - 7.20|
|52 Week Range||5.85 - 11.34|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.
The Jerusalem-based company said it had a loss of 18 cents per share. The drug maker posted revenue of $611,000 in the period. Oramed shares have decreased 2 percent since the beginning of the year. The ...
By Grant Zeng, CFA NASDAQ:ORMP The FDA Meeting Earlier today (Sept. 5, 2017), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that it has successfully concluded a meeting with the US FDA regarding ...
Categories: Yahoo FinanceGet free summary analysis Oramed Pharmaceuticals, Inc. reports financial results for the quarter ended May 31, 2017. Highlights Summary numbers: Revenues of USD 0.62 million, Net Earnings of USD -1.97 million. Change in operating cash flow of -5.89% compared to same period last year is about the same as change in earnings, likely no significant ... Read more (Read more...)
On a per-share basis, the Jerusalem-based company said it had a loss of 15 cents. The drug maker posted revenue of $617,000 in the period. Oramed shares have risen 36 percent since the beginning of the ...
Leptin, commonly known as the obesity, fat or satiety hormone, is a protein that is produced in fat cells which regulates and alters long-term food intake and energy expenditure. Leptin helps to inhibit hunger and regulate energy balance. Leptin has additionally been shown to suppress glucagon secretion and improve glucose levels in type I diabetes.
On a per-share basis, the Jerusalem-based company said it had a loss of 24 cents. The drug maker posted revenue of $611,000 in the period. Oramed shares have risen slightly more than 3 percent since the ...